Encapsulating peritoneal sclerosis

Chronic peritoneal dialysis (PD) can be complicated by encapsulating peritoneal sclerosis (EPS), a rare but the most severe complication associated with long-term PD. Morbidity and mortality are still high (range from 25% to 55%) especially in the first year after diagnosis. The international Society for Peritoneal Dialysis (ISPD) defined EPS by clinical signs of abdominal pain, bowel obstruction or weight loss in late stages of the disease. Clinical symptoms, radiologic findings and histologic criteria are the three diagnostic pillars.

[1]  G. Ott,et al.  Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral centre in Germany. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  K. Cransberg,et al.  Post-transplantation encapsulating peritoneal sclerosis in a young child. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  R. Krediet,et al.  Encapsulating peritoneal sclerosis: the state of affairs , 2011, Nature Reviews Nephrology.

[4]  M. Kimmel,et al.  Encapsulating peritoneal sclerosis - an overview. , 2011, Nephrologie & therapeutique.

[5]  J. Bargman,et al.  Encapsulating peritoneal sclerosis: a single-center experience and review of the literature , 2011, International Urology and Nephrology.

[6]  Hester F. Lingsma,et al.  RISK FACTORS ASSOCIATED WITH ENCAPSULATING PERITONEAL SCLEROSIS IN DUTCH EPS STUDY , 2011, Peritoneal Dialysis International.

[7]  M. Kimmel,et al.  DIFFERENCE IN THE EXPRESSION OF HORMONE RECEPTORS AND FIBROTIC MARKERS IN THE HUMAN PERITONEUM—IMPLICATIONS FOR THERAPEUTIC TARGETS TO PREVENT ENCAPSULATING PERITONEAL SCLEROSIS , 2011, Peritoneal Dialysis International.

[8]  N. Braun,et al.  A COLLABORATIVE APPROACH TO UNDERSTANDING EPS: THE EUROPEAN PERSPECTIVE , 2011, Peritoneal Dialysis International.

[9]  W. Gedroyc,et al.  Screening for encapsulating peritoneal sclerosis in patients on peritoneal dialysis: role of CT scanning. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Hester F. Lingsma,et al.  Posttransplantation Encapsulating Peritoneal Sclerosis Contributes Significantly to Mortality after Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Hester F. Lingsma,et al.  Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  R. Pararajasingam,et al.  Posttransplant Encapsulating Peritoneal Sclerosis Localized to the Terminal Ileum , 2010, Peritoneal Dialysis International.

[13]  J. Perl,et al.  Development of Encapsulating Peritoneal Sclerosis in a Renal Transplant Recipient on Sirolimus Immunotherapy , 2010, Peritoneal Dialysis International.

[14]  Sun-Hee Park,et al.  Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  David W. Johnson,et al.  Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. , 2010, Kidney international.

[16]  P. Conlon,et al.  Encapsulating peritoneal sclerosis: experience of a tertiary referral center , 2010, Renal failure.

[17]  R. Krediet.  Effects of icodextrin on the peritoneal membrane. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  S. Okuno,et al.  THE ROLE OF PERITONEAL LAVAGE AND THE PROGNOSTIC SIGNIFICANCE OF MESOTHELIAL CELL AREA IN PREVENTING ENCAPSULATING PERITONEAL SCLEROSIS , 2010, Peritoneal Dialysis International.

[19]  D. Struijk,et al.  EARLY DIAGNOSTIC MARKERS FOR ENCAPSULATING PERITONEAL SCLEROSIS: A CASE-CONTROL STUDY , 2010, Peritoneal Dialysis International.

[20]  D. Struijk,et al.  Encapsulating Peritoneal Sclerosis in a Peritoneal Dialysis Patient Using Biocompatible Fluids Only: Is Alport Syndrome a Risk Factor? , 2010, Peritoneal Dialysis International.

[21]  J. West-Mays,et al.  Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. , 2010, Matrix biology : journal of the International Society for Matrix Biology.

[22]  R. Goldschmeding,et al.  Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. , 2010, American journal of physiology. Renal physiology.

[23]  K. Oh,et al.  Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. , 2010, Kidney international.

[24]  T. Nabeshima,et al.  Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. , 2009, American journal of physiology. Renal physiology.

[25]  David W. Johnson,et al.  Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis: Position Paper for Ispd , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[26]  G. Garosi,et al.  No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis , 2009, International Urology and Nephrology.

[27]  A. Davenport,et al.  The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  J. Stoker,et al.  Computed Tomographic Findings Characteristic for Encapsulating Peritoneal Sclerosis: A Case-Control Study , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[29]  C. Shi,et al.  Prolonged Peritoneal Gene Expression Using a Helper-Dependent Adenovirus , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[30]  L. Rostaing,et al.  Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. , 2009, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[31]  E. Brown.  Computed Tomographic Scanning and Diagnosis of Encapsulating Peritoneal Sclerosis , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[32]  K. Simpson,et al.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[33]  S. Guest.  Tamoxifen Therapy for Encapsulating Peritoneal Sclerosis: Mechanism of Action and Update on Clinical Experiences , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[34]  E. Hur,et al.  Does Immunosuppressive Treatment Ameliorate Morphology Changes in Encapsulating Peritoneal Sclerosis? , 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[35]  M. Wilkie,et al.  Encapsulating Peritoneal Sclerosis: Clinical Significance and Implications , 2009, Nephron Clinical Practice.

[36]  W. Gedroyc,et al.  Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[37]  E. Hur,et al.  The Effects of Renin–angiotensin System Inhibition on Regression of Encapsulating Peritoneal Sclerosis , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[38]  N. Topley,et al.  How Can Genetic Advances Impact on Experimental Models of Encapsulating Peritoneal Sclerosis? , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[39]  K. Dohi,et al.  Recommendation of the Surgical Option for Treatment of Encapsulating Peritoneal Sclerosis , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[40]  H. Kawanishi,et al.  Icodextrin and Intraperitoneal Inflammation , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[41]  H. Nakamoto,et al.  Role of the Renin–angiotensin System in the Pathogenesis of Peritoneal Fibrosis , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[42]  P. Brenchley,et al.  Nutritional Management of Patients Undergoing Surgery following Diagnosis with Encapsulating Peritoneal Sclerosis , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[43]  J. Jimenez-Heffernan,et al.  Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. , 2008, Kidney international. Supplement.

[44]  V. Pichette,et al.  Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  T. Hosoya,et al.  Comparison Between the Pathology of Encapsulating Sclerosis and Simple Sclerosis of the Peritoneal Membrane in Chronic Peritoneal Dialysis , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[46]  T. Koji,et al.  Regeneration of Peritoneal Mesothelium in a Rat Model of Peritoneal Fibrosis , 2008, Renal failure.

[47]  R. Krediet,et al.  Cyclosporin A Induces Peritoneal Fibrosis and Angiogenesis during Chronic Peritoneal Exposure to a Glucose-Based, Lactate-Buffered Dialysis Solution in the Rat , 2007, Blood Purification.

[48]  T. Yoo,et al.  High glucose decreases collagenase expression and increases TIMP expression in cultured human peritoneal mesothelial cells. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  A. Scrimgeour,et al.  Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for adhesiolysis: a double-blind, randomized, controlled study. , 2007, Fertility and sterility.

[50]  M. Betjes,et al.  Posttransplant Encapsulating Peritoneal Sclerosis: A Worrying New Trend? , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[51]  Y. Tomino,et al.  Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  R. Zietse,et al.  Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  G. Woodrow,et al.  Successful treatment of fulminant encapsulating peritoneal sclerosis following fungal peritonitis with tamoxifen. , 2007, Clinical nephrology.

[54]  S. le Cessie,et al.  Impact of ACE Inhibitors and AII Receptor Blockers on Peritoneal Membrane Transport Characteristics in Long-Term Peritoneal Dialysis Patients , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[55]  J. Jimenez-Heffernan,et al.  Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. , 2007, Journal of the American Society of Nephrology : JASN.

[56]  B. Piraino,et al.  Why Is the Evidence Favoring Hemodialysis over Peritoneal Dialysis Misleading? , 2007, Seminars in dialysis.

[57]  S. Guest,et al.  Tuberculous Peritonitis Presenting as Encapsulating Peritoneal Sclerosis , 2007 .

[58]  Y. N. Park,et al.  Sclerosing Encapsulating Peritonitis (Abdominal Cocoon) after Abdominal Hysterectomy , 2007, The Korean journal of internal medicine.

[59]  N. Yorioka,et al.  Glucose‐Based PD Solution, But Not Icodextrin‐Based PD Solution, Induces Plasminogen Activator Inhibitor‐1 and Tissue‐Type Plasminogen Activator in Human Peritoneal Mesothelial Cells via ERK1/2 , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[60]  N. Braun,et al.  Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[61]  R. Krediet,et al.  Effluent Hydroxyproline in Experimental Peritoneal Dialysis , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[62]  H. Sugiyama,et al.  Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. , 2007, Kidney International.

[63]  W. Winkelmayer,et al.  Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. , 2007, Kidney international.

[64]  R. Saxena,et al.  Encapsulating Peritoneal Sclerosis Presenting with Recurrent Ascites and Tamoxifen: Case Reports and Review of the Literature , 2007, Renal failure.

[65]  P. Friend,et al.  Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. , 2006, Transplantation proceedings.

[66]  A. Krachler,et al.  Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[67]  U. Gafter,et al.  A worrying thought--could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[68]  S. Muto,et al.  The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  R. Tilton,et al.  Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[70]  P. Brenchley,et al.  An International Encapsulating Peritoneal Sclerosis Registry and DNA Bank: Why We Need One Now , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[71]  J. Sivak,et al.  Lens-specific expression of TGF-beta induces anterior subcapsular cataract formation in the absence of Smad3. , 2006, Investigative ophthalmology & visual science.

[72]  J. Jimenez-Heffernan,et al.  Epithelial-to-mesenchymal transition of the mesothelial cell--its role in the response of the peritoneum to dialysis. , 2006, Nephrology, Dialysis and Transplantation.

[73]  R. Krediet.  How to preserve residual renal function in patients with chronic kidney disease and on dialysis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  K. Flanders,et al.  A new model of anterior subcapsular cataract: involvement of TGFbeta/Smad signaling. , 2006, Molecular vision.

[75]  E. Mesic,et al.  Idiopathic retroperitoneal fibrosis: a rare onset of the illness caused by haemorrhagic fever with renal syndrome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[76]  J. Atchley,et al.  Four Consecutive Cases of Peritoneal Dialysis-Related Encapsulating Peritoneal Sclerosis Treated Successfully with Tamoxifen a , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[77]  T. Hendriksz,et al.  Brief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis , 2006, Annals of Internal Medicine.

[78]  M. Zeier,et al.  Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. , 2005, Journal of the American Society of Nephrology : JASN.

[79]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[80]  P. Brenchley,et al.  Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. , 2005, Kidney international.

[81]  J. Jimenez-Heffernan,et al.  Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[82]  D. Chan,et al.  Sclerosing encapsulating peritonitis in a liver transplant patient: a case report. , 2005, World journal of gastroenterology.

[83]  A. Teppo,et al.  Glucose-Free Dialysis Solutions: Inductors of Inflammation or Preservers of Peritoneal Membrane? , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[84]  Y. Kawaguchi,et al.  Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment , 2005, Clinical and Experimental Nephrology.

[85]  P. Pai,et al.  Successful Treatment of Encapsulating Peritoneal Sclerosis with Azathioprine and Prednisolone , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[86]  H. Oda,et al.  Pathology of Encapsulating Peritoneal Sclerosis , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[87]  Y. Kawaguchi,et al.  Recommendations on the Management of Encapsulating Peritoneal Sclerosis in Japan, 2005: Diagnosis, Predictive Markers, Treatment, and Preventive Measures , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[88]  H. Nakamoto.  Encapsulating Peritoneal Sclerosis—A Clinician's Approach to Diagnosis and Medical Treatment , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[89]  H. Kawanishi,et al.  Successful Surgical Management of Encapsulating Peritoneal Sclerosis , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[90]  M. Nakayama.  The Plasma Leak–to–Response Hypothesis: A Working Hypothesis on the Pathogenesis of Encapsulating Peritoneal Sclerosis after Long-Term Peritoneal Dialysis Treatment , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[91]  H. Kawanishi,et al.  Epidemiology of Encapsulating Peritoneal Sclerosis in Japan , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[92]  M. Flessner,et al.  The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.

[93]  T. Yoo,et al.  Clinical Characteristics of Dialysis Related Sclerosing Encapsulating Peritonitis: Multi-center Experience in Korea , 2005, Yonsei medical journal.

[94]  Joseph A. Giertych,et al.  Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution , 2005, The Lancet.

[95]  B. Maes,et al.  Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[96]  M. Nakayama,et al.  Encapsulating Peritoneal Sclerosis is a Separate Entity: Con , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[97]  J. West-Mays,et al.  Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. , 2005, Journal of the American Society of Nephrology : JASN.

[98]  N. Di Paolo,et al.  Sclerosing Peritonitis: A Nosological Entity , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[99]  W. Smit,et al.  The Difference in Causes of Early and Late Ultrafiltration Failure in Peritoneal Dialysis , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[100]  J. Kim,et al.  Angiotensin II Mediates High Glucose-Induced TGF-β1 and Fibronectin Upregulation in HPMC through Reactive Oxygen Species , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[101]  A. D. De Vriese.  The John F. Maher Recipient Lecture 2004: Rage in the Peritoneum , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[102]  Y. Kawaguchi,et al.  Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[103]  K. Newkirk,et al.  Tamoxifen Therapy for Riedel's Thyroiditis , 2004, The Laryngoscope.

[104]  T. Nishino,et al.  TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. , 2004, Kidney international.

[105]  H. Baloglu,et al.  Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[106]  T. Niwa,et al.  Advanced glycation end-products and peritoneal sclerosis. , 2004, Seminars in nephrology.

[107]  A. Roberts,et al.  Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis1 , 2004, The Journal of Immunology.

[108]  S. Clark,et al.  High‐dose tamoxifen and sulindac as first‐line treatment for desmoid tumors , 2004, Cancer.

[109]  Y. Asano,et al.  Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[110]  Y. Tomino,et al.  Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. , 2004, Kidney international.

[111]  J. Jimenez-Heffernan,et al.  Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis , 2004, Virchows Archiv.

[112]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[113]  Geraint T. Williams,et al.  The natural course of peritoneal membrane biology during peritoneal dialysis. , 2003, Kidney international. Supplement.

[114]  A. Roberts,et al.  Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. , 2003, The Journal of clinical investigation.

[115]  C. Pollock.  Dialysis Rounds
A Dialysis Case Presentation and Discussion
Edited by Roger A. Rodby: Bloody Ascites in a Patient After Transfer from Peritoneal Dialysis to Hemodialysis , 2003, Seminars in dialysis.

[116]  Hua Yang,et al.  Tacrolimus enhances transforming growth factor-&bgr;1 expression and promotes tumor progression , 2003, Transplantation.

[117]  R. Tilton,et al.  J Am Soc Nephrol 14: 2109–2118, 2003 Inhibition of the Interaction of AGE–RAGE Prevents Hyperglycemia-Induced Fibrosis of the Peritoneal Membrane , 2022 .

[118]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[119]  Geraint T. Williams,et al.  Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. , 2003, Kidney international. Supplement.

[120]  Po-Huang Lee,et al.  Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[121]  A. Yang,et al.  Myofibroblastic conversion of mesothelial cells. , 2003, Kidney international.

[122]  K. Eagle,et al.  Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. , 2003, Journal of the American Society of Nephrology : JASN.

[123]  J. Jimenez-Heffernan,et al.  Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. , 2003, The New England journal of medicine.

[124]  R. Rajani,et al.  Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[125]  S. Teraoka,et al.  The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. , 2002, Pharmacological research.

[126]  R. Kalluri,et al.  Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. , 2002, Kidney international.

[127]  Francis Ko,et al.  Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. , 2002, The Journal of surgical research.

[128]  H. Ha,et al.  Effects of Peritoneal Dialysis Solutions on the Secretion of Growth Factors and Extracellular Matrix Proteins by Human Peritoneal Mesothelial Cells , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[129]  Geraint T. Williams,et al.  Morphologic changes in the peritoneal membrane of patients with renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[130]  C. Cohen,et al.  Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. , 2002, Kidney international.

[131]  H. Kawanishi.  Encapsulating Peritoneal Sclerosis in Japan: Prospective Multicenter Controlled Study , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[132]  N. Yorioka,et al.  Glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. , 2001, Journal of the American Society of Nephrology : JASN.

[133]  T. Kawai,et al.  Sclerosing encapsulating peritonitis after renal transplantation: A case report , 2001 .

[134]  M. Kolb,et al.  Gene Transfer of Transforming Growth Factor- 1 to the Rat Peritoneum: Effects on Membrane Function , 2001 .

[135]  Jenq-Wen Huang,et al.  Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. , 2001, Kidney international.

[136]  M. Rela,et al.  Sclerosing encapsulating peritonitis after orthotopic liver transplantation. , 2001, American journal of surgery.

[137]  K. Moon,et al.  Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. , 2001, The Journal of laboratory and clinical medicine.

[138]  S. Kuriyama,et al.  Corticosteroid therapy in encapsulating peritoneal sclerosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[139]  W. Smit,et al.  Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up. , 2001, The Journal of laboratory and clinical medicine.

[140]  B. Grabensee,et al.  Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. , 2001, Kidney international. Supplement.

[141]  K. Sharma,et al.  Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. , 2001, Kidney international.

[142]  M. Davies,et al.  Production and Regulation of Matrix Metalloproteinases and Their Inhibitors by Human Peritoneal Mesothelial Cells , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[143]  C. Szeto,et al.  Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatory peritoneal dialysis. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[144]  S. Mujais,et al.  Encapsulating Peritoneal Sclerosis: Definition, Etiology, Diagnosis, and Treatment , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[145]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[146]  M. Park,et al.  Peritoneal Accumulation of Age and Peritoneal Membrane Permeability , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[147]  A. Donker,et al.  Peritoneal Kinetics and Mesothelial Markers in CCPD Using Icodextrin for Daytime Dwell for Two Years , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[148]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[149]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[150]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[151]  I. Pisoni,et al.  Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? , 1999, Journal of nephrology.

[152]  A. C. van der Wal,et al.  Vascular and Interstitial Changes in the Peritoneum of Capd Patients with Peritoneal Sclerosis , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[153]  Anabela S Rodrigues,et al.  Sclerosing Encapsulating Peritonitis: A Case Successfully Treated with Immunosuppression , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[154]  K. Nitta,et al.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[155]  R. Fagugli,et al.  Immunosuppressive treatment for sclerosing peritonitis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[156]  K. Yamagata,et al.  Intraperitoneal Hyaluronan Production in Stable Continuous Ambulatory Peritoneal Dialysis Patients , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[157]  H. Okada,et al.  Sclerosing encapsulating peritonitis associated with recurrent eosinophilic peritonitis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[158]  G. Kaysen,et al.  Factors influencing serum albumin in dialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[159]  S. Msika,et al.  Sclerosing Encapsulating Peritonitis: Early and Late Results of Surgical Management in 32 Cases , 1998, Digestive Surgery.

[160]  J. Bargman,et al.  Sclerosing peritonitis in continuous ambulatory peritoneal dialysis patients: one center's experience and review of the literature. , 1998, Advances in renal replacement therapy.

[161]  J. Hagège,et al.  PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1. , 1998, Kidney international.

[162]  T. Henle,et al.  3-Deoxyglucosone, a Promoter of Advanced Glycation end Products in Fluids for Peritoneal Dialysis , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[163]  I. Francis,et al.  CT appearance of sclerosing peritonitis in patients on chronic ambulatory peritoneal dialysis. , 1998, Journal of computer assisted tomography.

[164]  N. Hotta,et al.  A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[165]  A. Clarkson,et al.  Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[166]  M. Morganroth,et al.  Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. , 1997, Chest.

[167]  T. V. van Gulik,et al.  Peritoneal Sclerosis in Chronic Peritoneal Dialysis Patients: Analysis of Clinical Presentation, Risk Factors, and Peritoneal Transport Kinetics , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[168]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[169]  Y. Kawaguchi,et al.  Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[170]  G. Krestin,et al.  Imaging diagnosis of sclerosing peritonitis and relation of radiologic signs to the extent of the disease , 1995, Abdominal Imaging.

[171]  H. Rasmussen,et al.  PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. , 1995, Kidney international.

[172]  K. Yamada,et al.  Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. , 1994, Clinical nephrology.

[173]  D. Zemel,et al.  Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD. , 1994, Kidney international.

[174]  Marcus R. Wigan,et al.  Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[175]  G. Wolf,et al.  Angiotensin II as a renal growth factor. , 1993, Journal of the American Society of Nephrology : JASN.

[176]  M. Klagsbrun,et al.  The fibroblast growth factor family. , 1991, Cancer cells.

[177]  W. Lo,et al.  Sclerosing Peritonitis Complicating Prolonged Use of Chlorhexidine in Alcohol in the Connection Procedure for Continuous Ambulatory Peritoneal Dialysis , 1991, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[178]  G. W. Smith,et al.  Surgical aspects of sclerosing encapsulating peritonitis. , 1990, Archives of surgery.

[179]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[180]  J. Stouthard,et al.  The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[181]  J. Seltzer,et al.  H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. , 1988, The Journal of biological chemistry.

[182]  R. Wilkinson,et al.  Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory peritoneal dialysis. , 1987, Clinical science.

[183]  R. Gokal,et al.  ULTRAFILTRATION WITH AN ISOSMOTIC SOLUTION DURING LONG PERITONEAL DIALYSIS EXCHANGES , 1987, The Lancet.

[184]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[185]  C. Verger,et al.  PERITONEAL PERMEABILITY AND ENCAPSULATING PERITONITIS , 1985, The Lancet.

[186]  R. Freeman,et al.  Peritoneal dialysis complicated by fungal peritonitis and peritoneal fibrosis. , 1984, The American journal of medicine.

[187]  J. Bradley,et al.  SCLEROSING OBSTRUCTIVE PERITONITIS AFTER CONTINUOUS AMBULATORY PERITONEAL DIALYSIS , 1983, The Lancet.

[188]  W. Geis,et al.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. , 1980, Archives of internal medicine.

[189]  H. Baddeley,et al.  Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). , 1974, Lancet.

[190]  D. Struijk,et al.  The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[191]  G. Garosi.  Different aspects of peritoneal damage: fibrosis and sclerosis. , 2009, Contributions to nephrology.

[192]  K. Dohi,et al.  A case of encapsulating peritoneal sclerosis suspected to result from the use of icodextrin peritoneal solution. , 2009, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[193]  H. Kawanishi,et al.  Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis. , 2008, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[194]  K. Dohi,et al.  Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. , 2008, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[195]  D. Struijk,et al.  Encapsulating peritoneal sclerosis in patients on peritoneal dialysis. , 2008, The Netherlands journal of medicine.

[196]  F. Kirçelli,et al.  What does peritoneal thickness in peritoneal dialysis patients tell us? , 2007, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[197]  M. Dratwa,et al.  First Use of Tamoxifen in an HIV Patient with Encapsulating Peritoneal Sclerosis , 2007, Clinical drug investigation.

[198]  H. Kawanishi,et al.  Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. , 2006, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[199]  N. Yorioka,et al.  Tgf-beta1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[200]  F. Fend,et al.  Sclerosing encapsulating peritonitis: MRI diagnosis , 2005, European Radiology.

[201]  Youhua Liu.  Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. , 2004, Journal of the American Society of Nephrology : JASN.

[202]  K. Nitta,et al.  Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. , 2003, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[203]  R. Selgas,et al.  Clinical experience with tamoxifen in peritoneal fibrosing syndromes. , 2003, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[204]  T. Kawai,et al.  Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[205]  Y. Kawaguchi,et al.  Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[206]  Y. Kawaguchi,et al.  High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[207]  H. Kawanishi.  Surgical treatment for encapsulating peritoneal sclerosis. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[208]  Y. Kawaguchi,et al.  Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. , 2002, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[209]  S. Jenkins,et al.  Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. , 2001, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[210]  T. Kawai,et al.  Treatment options for encapsulating peritoneal sclerosis based on progressive stage. , 2001, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[211]  S. Mujais,et al.  Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[212]  R. Selgas,et al.  Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[213]  R. Mactier.  The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. , 2000, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[214]  W. Smit,et al.  Growth factors VEGF and TGF-beta1 in peritoneal dialysis. , 1999, The Journal of laboratory and clinical medicine.

[215]  C. Hawley,et al.  Sclerosing peritonitis: the experience in Australia. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[216]  T. Shigematsu,et al.  Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. , 1997, Kidney international.

[217]  K. Nitta,et al.  Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. , 1996, Nephron.

[218]  S. Komemushi,et al.  Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. , 1995, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[219]  W. Border,et al.  Transforming growth factor beta in tissue fibrosis. , 1994, The New England journal of medicine.

[220]  S. Bhandari,et al.  Sclerosing peritonitis: value of immunosuppression prior to surgery. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[221]  M. Mcmillan,et al.  Immunosuppression in sclerosing peritonitis. , 1993, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[222]  P. Holland.  Sclerosing encapsulating peritonitis in chronic ambulatory peritoneal dialysis. , 1990, Clinical radiology.

[223]  J. Rottembourg,et al.  Recovery of renal function in patients treated by CAPD. , 1989, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[224]  F. Brunner,et al.  Case-control study to determine the cause of sclerosing peritoneal disease. , 1988, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[225]  P. Strippoli,et al.  Severe abdominal complications in patients undergoing continuous ambulatory peritoneal dialysis. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.